- List
- By Topic
- On Map
- Search Details

Hematologic Malignancies | IPI-145
Need help? See RSS Feeds
Choose a feed type:

Hematologic Malignancies | IPI-145 (3 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02711852 | Active, not recruiting | A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
500 | All | 18 Years and older (Adult, Senior) | NCT02711852 | IPI-145-23 | April 2016 | June 2020 | December 2020 | March 17, 2016 | August 1, 2017 |
|
||
2 | NCT01476657 | Terminated | A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
210 | All | 18 Years and older (Adult, Senior) | NCT01476657 | IPI-145-02 | October 2011 | December 2016 | January 2017 | November 22, 2011 | August 1, 2017 |
|
||
3 | NCT01871675 | Completed | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
48 | All | 18 Years and older (Adult, Senior) | NCT01871675 | SCRI HEMREF 34 | May 2013 | June 2016 | June 2016 | June 7, 2013 | July 11, 2016 |
|
† Study has passed its completion date and status has not been verified in more than two years.